The model also allows expansion of very small biopsy material for long-term and repeated studies. However, the success rate for tumor "takes" in nude mice varies considerably among the different types of carcinomas (2, 3, 7, 8) . In breast, the successful rate for xenografting of tumor tissue is low (6% to 30%) (2, 7, 8) , whereas that of xenografting tumor cells has been reported to be as high as 69% (1, 6, 9, 10) . Other differences in breast xenograft takes appear related to the location of the graft, whether the fat pad is subcutaneous or mammary (8) , and co-injection with Matrigel (9) . These systems have yielded important insights into breast cancer progression, hormonal responses, and the expression of various oncogene and tumor suppressor genes.
Breast cancer, like many other cancers, is a clinically heterogeneous disease, which often makes diagnosis and treatment difficult. Little is known about the cellular and molecular events involved in the development and progression of this disease. Increasing evidence demonstrates the importance of tumor suppressor and protooncogenes in the progression of breast cancer. The overexpression or amplification of two of these genes, c-erbB-2 and p53, has been reported in 20% to 53% of breast carcinomas and is usually associated with the more aggressive tumors with poor prognosis (1 1-17) . Recently, attention has been focused on cyclin genes, whose involvement in signal transduction pathways regulates cell cycle progression (18) (19) (20) (21) (22) . Among the many different cyclin genes, cyclins DI and D3 are critical for controlling the movement of cells from G1 into the S phase of the cell cycle. Amplification of these genes usually leads to loss of normal growth control, and thus it is thought to play an important growth regulatory role in tumor development and progression. Cyclin DI and D3 are overexpressed in 10% to 80% of human breast cancers (22) (23) (24) (25) . Other studies suggest that there may be interrelations between cyclin Dl the other prognostic indicators, i.e., estrogen receptor, p53, and c-erbB-2 of breast cancer.
In this study, we examined immunohisto- (Fig. 1, neg. TO), and tumor 003 showed that approximately 39% of the tumor cells immunoreacted with antibody to estrogen receptor protein (Table 2 ). Immunohistochemical analysis also indicated levels of estrogen receptor-positive nuclei similar to the pathological reports in tumors 037, 195, and 337. The levels in tumor 003 were significantly higher, 39 versus 10, than the pathological reports. In all of the tumors positive for estrogen receptor, the cells immunoreactive for this protein were localized in the ducts (Fig. 1, pos. TO). This localization of estrogen receptor-positive cells was maintained in the T1 tumor in nude mice (Fig. 1, pos. T1) . Overall, The ages of the patients from which tumor samples were obtained ranged from 34 to 89 years of age. There was a significant correlation (p < 0.05) between patient age and T1 tumor growth in nude mice. Except for tumors obtained from 85-and 89-year-old patients, the successful xenografts occurred in tumors taken from patients in the eighth and ninth decade of life.
None of the To tumors obtained from patients of less than 72 years of age produced T1 tumors in nude mice.
Immunohistochemical Characterization of Onco-and Tumor Suppressor Proteins in To Tumors
The mean number of tumor cells that immunoreacted with antibody specific to cyclins DI and D2, and p53 and c-erbB-2 proteins was determined in 7 of the 16 To tissues. The staining patterns for each of these proteins were compared in both the To tumors (Table 2, Fig. 1 ). The number of cells immunoreactive with a particular antigen varied widely, from 0 to 87% among the To tumors (Table 2 ). These differences are shown in Fig. 1 where there is only faint background staining of some To tumors (Fig. 1, neg. TO), compared with intense cellular localization of stain in other To tumors (Fig. 1, pos. To). In those tumors that were immunoreactive to an antibody to a particular gene product, the staining patterns were characteristic of the localization of the protein in the cell. For example, stain for cyclins D1 and D3, and p53 were localized to the nucleus, whereas that for c-erbB-2 was specific to the cellular membrane. The cells that were immunoreactive were confined to the ductal regions of the tumor. Cyclin DI staining was moderate to strong in >76% of the cells in two of the seven To tumors characterized ( Table 2 , Fig. 1 , pos. To). These same two tumors were the only ones from this group which grew when transplanted in nude mice. In those To tumors which did not grow in nude mice, the number of cells expressing cyclin D1 was < 12% (Fig. 1, neg. TO). With cyclin D3, the staining patterns also varied from moderate to strong, but overall, they appeared to be more intense than that observed for cyclin DI (Fig. 1, pos There was strong staining of tumor cells lining the ducts for nuclear p53 protein (Fig. 1, pos. TO). Greater than 60% and 75% of the tumor cells in the two To tumors that grew in nude mice exhibited this staining pattern. In the To tumors that did not grow in nude mice, the number of cells exhibiting p53 protein varied from 0 (Fig. 1, neg. To) to 67%. The staining patterns for cerbB-2 protein were strong and more homogeneous among the tumor cells (Fig. 1, pos. To).
The number of cells producing c-erbB-2 protein was highest (75% and 80% positive cells) in the A number of correlations were demonstrated between markers in the tumor tissues (Table 3) weeks. In those To tumors that did not take in nude mice, the T, tumor tissue was quickly absorbed by the host. Successful xenografts exhibited an exponential growth phase between 2 and 9 weeks, during which time they were harvested for immunohistochemical characterization. To tumor tissue from Patient 003 was transplanted into the mammary fat pad of the nude mice as previously described for orthotopic transplant (8) . Both the tumor tissue transplanted into the fat pad and subcutaneously were absorbed within 1 week and 1 month, respectively, by the mouse. We observed a similar effect when enzymatically dispersed tumor tissue from Patient 089 was injected subcutaneously with Matrigel in nude mice as previously described (9) .
Immunohistochemical studies for cyclins DI and D3, estrogen receptor, p53, and c-erbB-2 were performed in the T1 tumors harvested at multiple time points, 1 to 4 weeks following transplantation of the original tumor (Fig. 1, pos. TI). In Fig. 1 (Table 4) as compared with the To tumor ( Table 2) . While the number of tumor cells staining positive for Cyclin DI are similar for tumor 195, the staining intensity appears to be greater in the T, than in the To tumor (Fig. 1, pos. T1 ).
There was a decrease in the number of cells immunoreactive for cyclin D3 in tumor 195 when it was transplanted into nude mice (Tables 2 and 4 ; Fig. 1, pos. T1 ). The number of tumor cells immunoreactive for cyclin D3 was similar in both To and T, tumors from Patient 037 ( Table 2 and 4). The staining patterns for p53 and c-erbB-2 proteins were similar for the To and T, tumors (Fig. 1, pos. To, T1). Cyclin DI, estrogen receptor, and p53 were expressed in the majority of cells (54% to 86%) in all of the T1 tumors (Table 4) . Cyclin D3 was expressed in 48 .5% of the cells of tissue 195, and it was highly expressed (70% to 75%) in the cells of the other T1 tumors. Only 37% of the cells of T1 tumor 144 expressed c-erbB-2, whereas this marker was ex- The phenotypic expression of the proliferative potential and aggressiveness of breast tumors has been associated with the increased activity of the tumor suppressor gene, p53 (9, 17, (38) (39) (40) (41) (42) (43) (44) (45) (46) . In these studies, protein-staining patterns associated with an increase in p53 activity and other genes associated with altering the kinetics of the cell cycle usually vary from tumor to tumor and between cells within the same tumor. We also observed a similar diversity in the expression of p53 gene product in (7, 9, (47) (48) (49) . Whereas this protein has been clinically associated with aggressive growth of breast tumor and poor clinical prognosis (7, 11, (47) (48) (49) (50) (51) (52) , the present data indicated that this gene product does not appear to be important in the continued growth of T1 tumors in nude mice. The present study suggests that cyclin Dl plays an important role in T1 tumor growth. Moreover, the increased presence of cyclin D proteins is strongly associated with many types of cancers, including breast (20, (22) (23) (24) 53, 54) . Cyclins DI and D3 proteins are expressed early in the G1, and they are necessary and rate limiting in the transition through the GI/S gate into the S phase of the cell cycle (18) (19) (20) (21) . Aberrant expression of cyclins can lead to a loss of normal growth control. Two previous studies indicated that 29% and 81% of primary breast carcinomas overexpress cyclin DI (22, 24) . One of these studies (24) also indicated that cyclin D3, which controls events later in G1, prior to S-phase entry, was overexpressed in approximately 10% of breast tumors. However, in these studies, overexpression of either cyclin DI or D3 was observed in over 69% of breast carcinomas, which suggests that overexpression of either the D1 or D3 cyclin may be sufficient to relieve the cell of its mitogenic stimulatory requirement (55) . Our studies indicated that 28% of the To tumors studied overexpress both cyclins DI and D3. These tumors grew as T1 tumors in the nude mice and continued to express high levels of cyclin DI. Whereas all the T1 tumors expressed high levels of cyclin DI, all but one T1 tumor expressed high levels of cyclin D3. In this tumor the percentage of cells expressing cyclin D3 declined from 70% in To to 48 .5% in T1. Another tumor that expressed low levels of DI but high levels of D3 did not grow in T1. These data suggest that cyclin Dl1 may be an important factor for tumor growth in the nude mouse and are consistent with the release of tumor cells from mitogenic stimulus. In conclusion, these studies indicate that there appears to be a diversity in the phenotypic expression of genes associated with the cellularity of breast tumors and that those genes involved in regulating progression through the cell cycle may be important factors in breast tumor progression.
